INTERLEUKIN-17A inhibitor, Taltz (ixekizumab) from Lilly is now listed on the PBS as an authority required listing for the treatment of patients with severe chronic plaque psoriasis, providing another option for afflicted people.
CLICK HERE for Taltz PI.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Feb 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Feb 17